Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

remibrutinib, MS experimental treatments | Multiple Sclerosis News Today | illustration of hands holding oral medicines

Vidofludimus Calcium for Multiple Sclerosis

Last updated June 16, 2022, by Lindsey Shapiro, PhD

Fact-checked by Ines Martins, PhD

FAQs about vidofludimus calcium in MS

Vidofludimus calcium is an experimental therapy that is still in clinical trials for multiple sclerosis. It is expected to lower inflammation and prevent MS damage by inhibiting the growth of certain activated immune cells. In clinical trials, vidofludimus calcium treatment resulted in a significant reduction in the number of brain lesions in people with relapsing-remitting multiple sclerosis. The therapy also showed some promising benefits in relapse rates and disability worsening among these patients.

Phase 3 clinical trials testing vidofludimus calcium for the treatment of relapsing forms of multiple sclerosis are underway, as are Phase 2 trials for progressive forms of the disease. According to Immunic Therapeutics, the therapy’s developer, these Phase 3 trials may support regulatory applications seeking approval for the medication from the U.S. Food and Drug Administration. It is too soon, however, to determine if or when the medication could be approved.

Clinical trials of vidofludimus calcium have not, and are not, enrolling multiple sclerosis patients who are pregnant or breastfeeding. Whether the therapy can be safely used in these situations is not known.

Some patients in clinical trials have seen benefits following six months of treatment with vidofludimus calcium. In the EMPhASIS Phase 2 trial, which investigated the therapy against a placebo in patients with relapsing-remitting multiple sclerosis, treatment significantly lowered the number of active brain lesions after about six months. But given that multiple sclerosis can manifest differently in every patient, individual responses to treatment also may vary.

While weight gain was not reported as a side effect of vidofludimus calcium in multiple sclerosis clinical trials, hair loss was experienced by some patients. It is recommended that patients talk with their healthcare providers if any unexpected side effects arise when using a new therapy.

Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Related Articles


Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.